07:00 , Aug 2, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Cerebral cavernous malformation 2 (CCM2); serine/threonine kinase 25 (STK25) In vitro studies suggest increasing STK25...
07:00 , Sep 8, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Inducible mouse models of cerebral cavernous malformations (CCM) Inducible mouse models of CCM could aid the development of new...
07:00 , Jul 22, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cerebral cavernous malformation (CCM) KRIT1 ankyrin repeat containing (KRIT1; CCM1); cerebral cavernous malformation 2 (CCM2); programmed cell...
07:00 , Jul 22, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) NK cells Studies in patient-derived cells and in mice suggest that depleting NK...
07:00 , Sep 17, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Brain cancer Cerebral...
08:00 , Jan 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease ...